Abstract:Abstract Background: Cancer-derived exosomes are considered to be the main driving force for cancer-induced metastasis niche formation at foreign sites, but the mechanism is unclear. Methods: Identification of differentially expressed miRNAs in exosomes by miRNA sequencing. Through a series of in vitro and in vivo experiments, it was studied that the tumor-derived exosome miR-3157-3p can be taken up by the endothelium and exert biological functions. The molecular mechanism of miR-3157-3p was confirmed by Western blot, luciferase test and rescue experiment. Finally, real-time fluorescence quantitative PCR and RNA in situ hybridization were used to evaluate the clinical relevance of miR-3157-3p expression. Result: In metastatic NSCLC patients, the expression level of miR-3157-3p in circulating exosomes was significantly higher than that of non-metastatic NSCLC patients. Here, we found that miR-3157-3p can be transferred from NSCLC cells to vascular endothelial cells through exosomes. Exosome miR-3157-3p has regulated the expression of VEGF / MMP2 / MMP9 and occludin in endothelial cells by targeting TIMP / KLF2, thereby promoted angiogenesis and increased vascular permeability. In addition, exosome miR-3157-3p from NSCLC cells enhances NSCLC metastasis in mouse lungs. Conclusion: Our work indicates that exosome miR-3157-3p is involved in the formation of pre-metastatic niche and may be used as a blood-based biomarker for NSCLC metastasis.

Non-small lung cancer cells-derived exosome miR-3157-3p primes pre-metastatic niche by inducing angiogenesis and vascular permeability